Capital Fund Management (CFM)’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,500
Closed -$8.88M 2473
2025
Q4
$8.88M Sell
11,500
-25,800
-69% -$17.5M 0.02% 903
2025
Q3
$21M Buy
37,300
+1,700
+5% +$961K 0.06% 495
2025
Q2
$18.7M Sell
35,600
-13,800
-28% -$7.7M 0.05% 484
2025
Q1
$31.3M Buy
49,400
+33,300
+207% +$22.9M 0.09% 311
2024
Q4
$11.5M Buy
+16,100
New +$13.5M 0.03% 693
2021
Q2
Sell
-11,400
Closed -$5.39M 1611
2021
Q1
$5.39M Buy
+11,400
New +$5.55M 0.06% 395
2020
Q2
Sell
-10,500
Closed -$5.13M 1464
2020
Q1
$5.13M Sell
10,500
-1,800
-15% -$742K 0.08% 304
2019
Q4
$4.62M Sell
12,300
-13,800
-53% -$4.64M 0.04% 563
2019
Q3
$7.24M Sell
26,100
-38,500
-60% -$11.4M 0.07% 368
2019
Q2
$20.2M Buy
64,600
+51,300
+386% +$17.1M 0.18% 150
2019
Q1
$5.46M Sell
13,300
-10,200
-43% -$4.2M 0.05% 463
2018
Q4
$8.78M Sell
23,500
-25,000
-52% -$9.15M 0.08% 347
2018
Q3
$19.6M Sell
48,500
-44,100
-48% -$16.8M 0.11% 284
2018
Q2
$31.9M Buy
92,600
+14,300
+18% +$4.47M 0.17% 176
2018
Q1
$27M Buy
78,300
+6,900
+10% +$2.4M 0.16% 175
2017
Q4
$26.8M Buy
71,400
+9,500
+15% +$3.85M 0.15% 167
2017
Q3
$27.7M Sell
61,900
-17,600
-22% -$8.37M 0.2% 149
2017
Q2
$39M Buy
79,500
+77,000
+3,080% +$33.7M 0.31% 80
2017
Q1
$969K Sell
2,500
-600
-19% -$222K 0.01% 927
2016
Q4
$1.14M Sell
3,100
-12,400
-80% -$4.72M 0.01% 971
2016
Q3
$6.23M Sell
15,500
-27,500
-64% -$11M 0.06% 406
2016
Q2
$15M Buy
43,000
+32,500
+310% +$12.5M 0.14% 185
2016
Q1
$3.79M Buy
10,500
+9,000
+600% +$3.71M 0.04% 521
2015
Q4
$814K Sell
1,500
-3,100
-67% -$1.68M 0.01% 953
2015
Q3
$2.14M Sell
4,600
-400
-8% -$215K 0.02% 594
2015
Q2
$2.55M Buy
+5,000
New +$2.44M 0.03% 545
2014
Q2
Sell
-8,700
Closed -$2.61M 1882
2014
Q1
$2.61M Buy
+8,700
New +$2.68M 0.03% 578
2013
Q4
Sell
-7,300
Closed -$2.28M 1810
2013
Q3
$2.28M Sell
7,300
-20,000
-73% -$5.26M 0.03% 598
2013
Q2
$6.14M Buy
+27,300
New +$6.36M 0.09% 276

Other funds holding REGN

Capital Fund Management (CFM)'s REGN Position: Q4 2025 in Review

Capital Fund Management (CFM) sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 58,834 shares — an estimated $40M sold.

Capital Fund Management (CFM) first reported a position in REGN in Q1 2014 and held it in 18 quarters. The position peaked at $58.9M in Q1 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Capital Fund Management (CFM) reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 58,834 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $40M.
  • Capital Fund Management (CFM) first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 18 quarters.
  • Capital Fund Management (CFM)'s Regeneron Pharmaceuticals position peaked at $58.9M in Q1 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2025, filed 17 Feb 2026.